# Study of ST-1898 in Advanced Renal Cell Carcinoma

> **NCT06127238** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Beijing Scitech-Mq Pharmaceuticals Limited** · enrollment: 90 (estimated)

## Conditions studied

- Advanced Renal Cell Carcinoma

## Interventions

- **DRUG:** ST-1898 tablets

## Key facts

- **NCT ID:** NCT06127238
- **Lead sponsor:** Beijing Scitech-Mq Pharmaceuticals Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-07
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06127238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06127238, "Study of ST-1898 in Advanced Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06127238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*